Arrowhead Pharmaceuticals (ARWR) News Today $13.80 -0.13 (-0.93%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$13.82 +0.02 (+0.18%) As of 03/27/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 12-Month Low - Time to Sell?March 27 at 11:58 AM | marketbeat.comVirtu Financial LLC Makes New $381,000 Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Virtu Financial LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 20,266 shares of the biotechnologyMarch 27 at 4:21 AM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of "Moderate Buy" from BrokeragesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) has been given an average rating of "Moderate Buy" by the ten research firms that are presently covering the firm, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and six have given aMarch 27 at 2:37 AM | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 4.8% - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 4.8% - Time to Sell?March 26 at 1:28 PM | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the companyMarch 25 at 8:04 PM | finance.yahoo.comHighTower Advisors LLC Cuts Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)HighTower Advisors LLC reduced its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 39.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 75,056 shares of the biotechnology compaMarch 25 at 3:27 AM | marketbeat.comIntech Investment Management LLC Has $1.67 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Intech Investment Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 160.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 88,661 shares of the biotechnology company's stock aMarch 23, 2025 | marketbeat.comFY2026 Earnings Forecast for ARWR Issued By Leerink PartnrsMarch 22, 2025 | americanbankingnews.comArrowhead Pharmaceuticals Is Finally ArrivingMarch 21, 2025 | seekingalpha.comLeerink Partnrs Has Pessimistic View of ARWR FY2026 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Leerink Partnrs cut their FY2026 earnings estimates for Arrowhead Pharmaceuticals in a note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnMarch 21, 2025 | marketbeat.comPrivium Fund Management B.V. Increases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Privium Fund Management B.V. boosted its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 14.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 380,586 shares of the biotechnology companMarch 20, 2025 | marketbeat.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone Sells 51,425 SharesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This represents a 1.25 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.March 18, 2025 | marketbeat.comInsider Selling: Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells 51,425 Shares of StockMarch 18, 2025 | insidertrades.comWealthfront Advisers LLC Buys New Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Wealthfront Advisers LLC bought a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 109,566 shares of the biotechnology companyMarch 16, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Up 8.4% - Still a Buy?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 8.4% - Still a Buy?March 13, 2025 | marketbeat.comKing Luther Capital Management Corp Makes New Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)King Luther Capital Management Corp bought a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 76,965 shares of the biotechnology company'sMarch 13, 2025 | marketbeat.comArrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3March 12, 2025 | nasdaq.comBank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Bank of New York Mellon Corp lessened its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 4.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 830,058 shares of the biotechnology companMarch 12, 2025 | marketbeat.comArrowhead data supports blockbuster potential of ARO-C3, says H.C. WainwrightMarch 10, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low - Time to Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 52-Week Low - What's Next?March 10, 2025 | marketbeat.comArrowhead announces topline results from ARO-C3 trialMarch 10, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA NephropathyMarch 10, 2025 | finance.yahoo.comEdgestream Partners L.P. Makes New $2.26 Million Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Edgestream Partners L.P. acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 120,411 shares oMarch 10, 2025 | marketbeat.comArrowhead presents data on candidates to treat obesity, metabolic diseasesMarch 6, 2025 | markets.businessinsider.comChristopher Richard Anzalone Sells 133,333 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) StockArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) CEO Christopher Richard Anzalone sold 133,333 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the sale, the chief executive officer now owns 3,773,802 shares in the company, valued at $64,230,110.04. This trade represents a 3.41 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.March 6, 2025 | marketbeat.comArrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic DiseasesMarch 6, 2025 | businesswire.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $2,269,327.66 in StockMarch 6, 2025 | insidertrades.comArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Holdings Increased by Fisher Asset Management LLCFisher Asset Management LLC increased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 16.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 142,939 shares of the biotechnology company's stock after puMarch 6, 2025 | marketbeat.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low - Here's WhyArrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week Low - Should You Sell?March 5, 2025 | marketbeat.comPinion Investment Advisors LLC Makes New Investment in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Pinion Investment Advisors LLC acquired a new stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,March 4, 2025 | marketbeat.comInteresting ARWR Call Options For April 17thFebruary 26, 2025 | nasdaq.comArrowhead presents preclinical results on ARO-ALK7February 25, 2025 | markets.businessinsider.comArrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of ObesityFebruary 25, 2025 | businesswire.comState of New Jersey Common Pension Fund D Increases Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)State of New Jersey Common Pension Fund D lifted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 40.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor ownedFebruary 23, 2025 | marketbeat.comEmpowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)Empowered Funds LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 14,273 shares of the biotechnology comFebruary 22, 2025 | marketbeat.comArrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | insidermonkey.comArrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy NowFebruary 20, 2025 | msn.comArrowhead Pharmaceuticals: Progress During Adverse Market ConditionsFebruary 19, 2025 | seekingalpha.comFat, not muscle: drugmakers in race for next weight-loss breakthroughFebruary 19, 2025 | reuters.comEquities Analysts Offer Predictions for ARWR FY2025 EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at B. Riley increased their FY2025 earnings per share estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Thursday, February 13th. B. Riley analyst M. Mamtani now anticipates that the bFebruary 17, 2025 | marketbeat.comQ2 Earnings Estimate for ARWR Issued By HC WainwrightArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Wednesday, February 12th. HC Wainwright analyst P. Trucchio anticipates that the biotechnolFebruary 17, 2025 | marketbeat.comB. Riley Reiterates "Buy" Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR)B. Riley reissued a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a report on Friday.February 15, 2025 | marketbeat.comZacks Small Cap Issues Negative Estimate for ARWR EarningsArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Zacks Small Cap reduced their Q2 2025 earnings estimates for shares of Arrowhead Pharmaceuticals in a research note issued to investors on Wednesday, February 12th. Zacks Small Cap analyst D. Bautz now forFebruary 15, 2025 | marketbeat.comArrowhead price target lowered to $38 from $51 at B. RileyFebruary 14, 2025 | markets.businessinsider.comB.Riley Financial Sticks to Their Buy Rating for Arrowhead Pharmaceuticals (ARWR)February 14, 2025 | markets.businessinsider.comLeerink Partnrs Brokers Raise Earnings Estimates for ARWRArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Research analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Arrowhead Pharmaceuticals in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnologyFebruary 13, 2025 | marketbeat.comArrowhead Pharmaceuticals' (ARWR) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Wednesday.February 13, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Edwards Lifesciences (EW), Arrowhead Pharmaceuticals (ARWR) and Exelixis (EXEL)February 13, 2025 | markets.businessinsider.comARWR: Multiple Catalysts Ahead in 2025…February 13, 2025 | finance.yahoo.comArrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 5% - Should You Sell?Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 5% - Should You Sell?February 12, 2025 | marketbeat.com Remove Ads Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Media Mentions By Week ARWR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARWR News Sentiment▼0.430.78▲Average Medical News Sentiment ARWR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARWR Articles This Week▼136▲ARWR Articles Average Week Remove Ads Get Arrowhead Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Sarepta Therapeutics News Revolution Medicines News BridgeBio Pharma News Lantheus News TG Therapeutics News Legend Biotech News Axsome Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARWR) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ARWR Stock Free ARWR Stock Alerts